Incurin for Dogs - Tablets 1 mg, 30 Ct. - [Urinary Health]

Incurin Tablets for Dogs are a veterinarian-prescribed treatment specifically formulated to manage estrogen-responsive urinary incontinence in spayed female dogs (those that have undergone an ovariohysterectomy). Backed by over a decade of global use, Incurin offers a reliable, effective solution for improving bladder control in affected dogs.

Key Benefits

• Clinically proven to reduce or eliminate episodes of urinary incontinence in spayed female dogs
• Convenient once-daily oral dosing
• Simple, standardized starting dose for all female dogs regardless of weight or age
• Allows flexible dose titration to the lowest effective amount

How It Works

Incurin contains estriol, a naturally occurring estrogen. Estriol helps restore urethral sphincter tone by compensating for estrogen loss that occurs after spaying. By increasing the resting muscle tone in the urethra, it helps dogs regain bladder control and reduce involuntary urine leakage. Treatment starts with a once-daily dose of two tablets, with gradual adjustment to identify the minimum effective dose for long-term use.

Indications

Incurin Tablets are indicated for the control of estrogen-responsive urinary incontinence in ovariohysterectomized (spayed) female dogs. This condition is often associated with reduced estrogen levels post-surgery, which can lead to weakened urinary sphincter control and involuntary leakage.

Incurin is a registered trademark of Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co., Inc.

View Incurin Drug Facts Sheet (PDF)

Dosage and Administration

Incurin Tablets are administered orally once daily and the dosage is not dependent on the dog's body weight. All dogs should begin with an initial dose of 2 mg (2 tablets) once daily for a minimum of 14 days. Once urinary incontinence is controlled, the dose should be gradually reduced to identify the lowest effective dose:

• Decrease to 1 mg (1 tablet) once daily
• Then reduce to 0.5 mg (½ tablet) once daily
• Minimum of 7 days between each adjustment
• If stable, dosing may be reduced to every other day

Do not exceed 2 mg per day (2 tablets). If there is no improvement at the 2 mg dose, re-evaluate the diagnosis with your veterinarian.

Caution

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Human Safety Warnings

Not for human use. Keep out of reach of children. Women who are pregnant, breastfeeding, or of childbearing age should exercise caution when handling Incurin Tablets. Wash hands thoroughly with soap and water after administration. If accidental ingestion occurs, seek medical attention immediately.

Animal Warnings

Some estrogens have been linked to bone marrow suppression and increased risk of mammary tumors. However, safety studies and post-market data suggest that estriol in Incurin poses minimal risk when used as directed.

Precautions

• Evaluate other causes of urinary incontinence before starting treatment.
• Do not use concurrently with other estrogens.
• Concomitant use with glucocorticoids has not been studied.
• Use in dogs with liver disease has not been evaluated.
• Safety has not been established in intact females, pregnant or lactating dogs, males, or dogs under 1 year of age.

Possible Side Effects

Monitor for signs of gastrointestinal upset, estrogenic effects, or changes in vulva appearance. Contact your veterinarian if side effects occur.

Storage

Store at or below 25°C (77°F). Short excursions up to 40°C (104°F) are permitted.